Ardent Health (ARDT) to Announce Earnings on Tuesday

Ardent Health (NYSE:ARDTGet Free Report) is expected to release its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect the company to post earnings of $0.1817 per share and revenue of $1.5897 billion for the quarter. Ardent Health has set its FY 2026 guidance at 0.900-1.270 EPS. Investors may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 10:00 AM ET.

Ardent Health (NYSE:ARDTGet Free Report) last released its quarterly earnings results on Tuesday, May 5th. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.18 by $0.10. The company had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.58 billion. Ardent Health had a return on equity of 13.85% and a net margin of 2.09%. On average, analysts expect Ardent Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Ardent Health Stock Performance

Shares of ARDT stock opened at $10.67 on Friday. The company has a market capitalization of $1.53 billion, a P/E ratio of 11.23, a P/E/G ratio of 2.51 and a beta of 0.76. The business’s 50 day moving average is $9.79 and its two-hundred day moving average is $9.41. The company has a current ratio of 2.12, a quick ratio of 2.00 and a debt-to-equity ratio of 0.62. Ardent Health has a 12-month low of $7.71 and a 12-month high of $15.48.

Analysts Set New Price Targets

A number of analysts have recently commented on ARDT shares. Truist Financial cut their price objective on Ardent Health from $13.00 to $12.00 and set a “buy” rating for the company in a research report on Tuesday, July 14th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Ardent Health in a research report on Friday, June 12th. UBS Group lifted their price target on shares of Ardent Health from $13.00 to $13.50 and gave the company a “buy” rating in a research note on Thursday, May 7th. Wall Street Zen lowered shares of Ardent Health from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Finally, Royal Bank Of Canada reduced their price objective on shares of Ardent Health from $13.00 to $12.00 and set an “outperform” rating for the company in a research report on Thursday, July 9th. Seven analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Ardent Health currently has an average rating of “Hold” and a consensus target price of $14.04.

View Our Latest Stock Report on Ardent Health

Insider Transactions at Ardent Health

In other news, CFO Alfred Lumsdaine purchased 10,000 shares of the stock in a transaction dated Friday, June 5th. The shares were purchased at an average cost of $8.81 per share, with a total value of $88,100.00. Following the completion of the purchase, the chief financial officer directly owned 329,183 shares of the company’s stock, valued at approximately $2,900,102.23. The trade was a 3.13% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders own 1.90% of the company’s stock.

Institutional Investors Weigh In On Ardent Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Goldentree Asset Management LP boosted its position in Ardent Health by 99.7% during the fourth quarter. Goldentree Asset Management LP now owns 2,303,113 shares of the company’s stock worth $20,302,000 after acquiring an additional 1,150,000 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in Ardent Health by 1,684.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 767,862 shares of the company’s stock valued at $10,558,000 after acquiring an additional 724,841 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in Ardent Health by 75.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,634,822 shares of the company’s stock valued at $22,332,000 after acquiring an additional 703,739 shares during the last quarter. Bridgeway Capital Management LLC raised its holdings in Ardent Health by 108.2% in the 4th quarter. Bridgeway Capital Management LLC now owns 946,571 shares of the company’s stock valued at $8,358,000 after acquiring an additional 491,961 shares during the last quarter. Finally, Hotchkis & Wiley Capital Management LLC purchased a new position in Ardent Health in the 3rd quarter worth approximately $6,377,000.

Ardent Health Company Profile

(Get Free Report)

Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company’s integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.

Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.

Read More

Earnings History for Ardent Health (NYSE:ARDT)

Receive News & Ratings for Ardent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardent Health and related companies with MarketBeat.com's FREE daily email newsletter.